PURPOSE: The purpose of this study was to monitor the metabolic effects of temozolomide (TMZ) chemotherapy in malignant gliomas by means of repeated positron emission tomography (PET) with [(11)C]methionine (MET). METHODS: Fifteen patients with histologically proven malignant glioma were treated by TMZ chemotherapy. MET-PET studies were performed before and after the third cycle of TMZ chemotherapy in all patients, and in 12 patients also after the sixth cycle. Gadolinium-enhanced MRI studies were performed in 12 patients before the first and after the sixth cycle. Clinical status was assessed by the modified Rankin scale. Long-term outcome was assessed by calculating the time to progression (TTP) in months. RESULTS: Decline in MET uptake during therapy corresponded to a stable clinical status. The median TTP was significantly longer in patients with decline in MET uptake than in those with increasing MET uptake (23 vs 3.5 months; p=0.01, log rank test). There was no significant correlation between change in MET uptake and change in contrast enhancement during treatment for all patients. CONCLUSION: The present data demonstrate that clinical stability, which is often achieved under TMZ chemotherapy of malignant glioma, corresponds to a decline in or stability of tumour amino acid metabolism. Tumour responses can already be demonstrated with MET-PET after three cycles of chemotherapy, and absence of progression at that time indicates a high probability of further stability during the next three cycles. A reduction in MET uptake during TMZ treatment predicts a favourable clinical outcome. Molecular imaging of amino acid uptake by MET-PET offers a new method of measurement of the biological activity of recurrent glioma.
PURPOSE: The purpose of this study was to monitor the metabolic effects of temozolomide (TMZ) chemotherapy in malignant gliomas by means of repeated positron emission tomography (PET) with [(11)C]methionine (MET). METHODS: Fifteen patients with histologically proven malignant glioma were treated by TMZ chemotherapy. MET-PET studies were performed before and after the third cycle of TMZ chemotherapy in all patients, and in 12 patients also after the sixth cycle. Gadolinium-enhanced MRI studies were performed in 12 patients before the first and after the sixth cycle. Clinical status was assessed by the modified Rankin scale. Long-term outcome was assessed by calculating the time to progression (TTP) in months. RESULTS: Decline in MET uptake during therapy corresponded to a stable clinical status. The median TTP was significantly longer in patients with decline in MET uptake than in those with increasing MET uptake (23 vs 3.5 months; p=0.01, log rank test). There was no significant correlation between change in MET uptake and change in contrast enhancement during treatment for all patients. CONCLUSION: The present data demonstrate that clinical stability, which is often achieved under TMZ chemotherapy of malignant glioma, corresponds to a decline in or stability of tumour amino acid metabolism. Tumour responses can already be demonstrated with MET-PET after three cycles of chemotherapy, and absence of progression at that time indicates a high probability of further stability during the next three cycles. A reduction in MET uptake during TMZ treatment predicts a favourable clinical outcome. Molecular imaging of amino acid uptake by MET-PET offers a new method of measurement of the biological activity of recurrent glioma.
Authors: Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss Journal: Clin Cancer Res Date: 2004-11-01 Impact factor: 12.531
Authors: L Ostergaard; F H Hochberg; J D Rabinov; A G Sorensen; M Lev; L Kim; R M Weisskoff; R G Gonzalez; C Gyldensted; B R Rosen Journal: J Neurosurg Date: 1999-02 Impact factor: 5.115
Authors: C S Brock; H Young; S M O'Reilly; J Matthews; S Osman; H Evans; E S Newlands; P M Price Journal: Br J Cancer Date: 2000-02 Impact factor: 7.640
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs Journal: Br J Radiol Date: 2011-12 Impact factor: 3.039
Authors: Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht Journal: Eur J Nucl Med Mol Imaging Date: 2010-01 Impact factor: 9.236
Authors: Norbert Galldiks; Lutz W Kracht; Frank Berthold; Hrvoje Miletic; Johannes C Klein; Karl Herholz; Andreas H Jacobs; Wolf-Dieter Heiss Journal: J Neurooncol Date: 2009-07-04 Impact factor: 4.130